233 related articles for article (PubMed ID: 20562330)
1. Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders.
Jones K; Nourse JP; Morrison L; Nguyen-Van D; Moss DJ; Burrows SR; Gandhi MK
Blood; 2010 Sep; 116(13):2245-52. PubMed ID: 20562330
[TBL] [Abstract][Full Text] [Related]
2. Long-term carriers generate Epstein-Barr virus (EBV)-specific CD4(+) and CD8(+) polyfunctional T-cell responses which show immunodominance hierarchies of EBV proteins.
Ning RJ; Xu XQ; Chan KH; Chiang AK
Immunology; 2011 Oct; 134(2):161-71. PubMed ID: 21896011
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD.
Sebelin-Wulf K; Nguyen TD; Oertel S; Papp-Vary M; Trappe RU; Schulzki A; Pezzutto A; Riess H; Subklewe M
Transpl Immunol; 2007 Apr; 17(3):203-10. PubMed ID: 17331848
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
Kalra M; Gerdemann U; Luu JD; Ngo MC; Leen AM; Louis CU; Rooney CM; Gottschalk S
Cytotherapy; 2019 Feb; 21(2):212-223. PubMed ID: 30396848
[TBL] [Abstract][Full Text] [Related]
5. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
Nowakowska J; Stuehler C; Egli A; Battegay M; Rauser G; Bantug GR; Brander C; Hess C; Khanna N
Cytotherapy; 2015 Sep; 17(9):1280-91. PubMed ID: 26276009
[TBL] [Abstract][Full Text] [Related]
6. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
[TBL] [Abstract][Full Text] [Related]
7. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.
Münz C; Bickham KL; Subklewe M; Tsang ML; Chahroudi A; Kurilla MG; Zhang D; O'Donnell M; Steinman RM
J Exp Med; 2000 May; 191(10):1649-60. PubMed ID: 10811859
[TBL] [Abstract][Full Text] [Related]
8. Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation.
Icheva V; Kayser S; Wolff D; Tuve S; Kyzirakos C; Bethge W; Greil J; Albert MH; Schwinger W; Nathrath M; Schumm M; Stevanovic S; Handgretinger R; Lang P; Feuchtinger T
J Clin Oncol; 2013 Jan; 31(1):39-48. PubMed ID: 23169501
[TBL] [Abstract][Full Text] [Related]
9. Full-length EBNA1 mRNA-transduced dendritic cells stimulate cytotoxic T lymphocytes recognizing a novel HLA-Cw*0303- and -Cw*0304-restricted epitope on EBNA1-expressing cells.
Ito Y; Demachi-Okamura A; Ohta R; Akatsuka Y; Nishida K; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
J Gen Virol; 2007 Mar; 88(Pt 3):770-780. PubMed ID: 17325349
[TBL] [Abstract][Full Text] [Related]
10. The role of virus-specific CD4+ T cells in the control of Epstein-Barr virus infection.
Mautner J; Bornkamm GW
Eur J Cell Biol; 2012 Jan; 91(1):31-5. PubMed ID: 21458882
[TBL] [Abstract][Full Text] [Related]
11. EBV-specific T-cell immunity in pediatric solid organ graft recipients with posttransplantation lymphoproliferative disease.
Wilsdorf N; Eiz-Vesper B; Henke-Gendo C; Diestelhorst J; Oschlies I; Hussein K; Pape L; Baumann U; Tönshoff B; Pohl M; Höcker B; Wingen AM; Klapper W; Kreipe H; Schulz TF; Klein C; Maecker-Kolhoff B
Transplantation; 2013 Jan; 95(1):247-55. PubMed ID: 23222899
[TBL] [Abstract][Full Text] [Related]
12. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2.
Lünemann JD; Jelcić I; Roberts S; Lutterotti A; Tackenberg B; Martin R; Münz C
J Exp Med; 2008 Aug; 205(8):1763-73. PubMed ID: 18663124
[TBL] [Abstract][Full Text] [Related]
13. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis.
Lünemann JD; Edwards N; Muraro PA; Hayashi S; Cohen JI; Münz C; Martin R
Brain; 2006 Jun; 129(Pt 6):1493-506. PubMed ID: 16569670
[TBL] [Abstract][Full Text] [Related]
14. Variable EBV DNA load distributions and heterogeneous EBV mRNA expression patterns in the circulation of solid organ versus stem cell transplant recipients.
Greijer AE; Stevens SJ; Verkuijlen SA; Juwana H; Fleig SC; Verschuuren EA; Hepkema BG; Cornelissen JJ; Brooimans RA; Verdonck LF; Middeldorp JM
Clin Dev Immunol; 2012; 2012():543085. PubMed ID: 23346186
[TBL] [Abstract][Full Text] [Related]
15. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.
Taylor GS; Haigh TA; Gudgeon NH; Phelps RJ; Lee SP; Steven NM; Rickinson AB
J Virol; 2004 Jan; 78(2):768-78. PubMed ID: 14694109
[TBL] [Abstract][Full Text] [Related]
16. Widespread sequence variation in Epstein-Barr virus nuclear antigen 1 influences the antiviral T cell response.
Bell MJ; Brennan R; Miles JJ; Moss DJ; Burrows JM; Burrows SR
J Infect Dis; 2008 Jun; 197(11):1594-7. PubMed ID: 18419576
[TBL] [Abstract][Full Text] [Related]
17. Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation.
Nikiforow S; Bottomly K; Miller G; Münz C
J Virol; 2003 Nov; 77(22):12088-104. PubMed ID: 14581546
[TBL] [Abstract][Full Text] [Related]
18. CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1.
Lee SP; Brooks JM; Al-Jarrah H; Thomas WA; Haigh TA; Taylor GS; Humme S; Schepers A; Hammerschmidt W; Yates JL; Rickinson AB; Blake NW
J Exp Med; 2004 May; 199(10):1409-20. PubMed ID: 15148339
[TBL] [Abstract][Full Text] [Related]
19. Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease.
Vickers MA; Wilkie GM; Robinson N; Rivera N; Haque T; Crawford DH; Barry J; Fraser N; Turner DM; Robertson V; Dyer P; Flanagan P; Newlands HR; Campbell J; Turner ML
Br J Haematol; 2014 Nov; 167(3):402-10. PubMed ID: 25066775
[TBL] [Abstract][Full Text] [Related]
20. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.
Davis JE; Moss DJ
Tissue Antigens; 2004 Apr; 63(4):285-92. PubMed ID: 15009802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]